An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung

Tree, Julia A.; Bembridge, Gary P.; Hou, Sam; Taylor, Geraldine; Fashola-Stone, Elizabeth; Melero, José A.; Cranage, Martin

doi:10.1016/j.vaccine.2003.11.069

Cited by 16 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This nature of endogenous protein expression has been suggested to avoid interference by maternal antibodies prevalent in young infants [42, 43]. Immunization with plasmid DNAs encoding an RSV F or G protein alone or in combination with plasmids encoding cytokines was able to induce IgG2a isotype antibody responses and Th1 type INF-γ or Th1/Th2 type cytokine immune responses [9, 44].…”

Section: Discussionmentioning

confidence: 99%

Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus

Lee

Kwon

Hwang

et al. 2014

Vaccine

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a major viral agent causing significant morbidity and mortality in young infants and the elderly. There is no licensed vaccine against RSV and it is a high priority to develop a safe RSV vaccine. We determined the immunogenicity and protective efficacy of combined virus-like particle and DNA vaccines presenting RSV glycoproteins (Fd.VLP) in comparison with formalin inactivated RSV (FI-RSV). Immunization of mice with Fd.VLP induced higher ratios of IgG2a/IgG1 antibody responses compared to those with FI-RSV. Upon live RSV challenge, Fd.VLP and FI-RSV vaccines were similarly effective in clearing lung viral loads. However, FI-RSV immunized mice showed a substantial weight loss and high levels of T helper type 2 (Th2) cytokines as well as extensive lung histopathology and eosinophil infiltration. In contrast, Fd.VLP immunized mice did not exhibit Th2 type cytokines locally and systemically, which might contribute to preventing vaccine-associated RSV lung disease. These results indicate that virus-like particles in combination with DNA vaccines represent a potential approach for developing a safe and effective RSV vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus

Lee

Kwon

Hwang

et al. 2014

Vaccine

View full text Add to dashboard Cite

show abstract

“…Furthermore, DNA vaccines also provide long-term immunity against viruses, a highly desirable property for a practical RSV vaccine (Justewicz and Webster, 1996). DNA vaccines against RSV are under investigation and several of these induce protective immune responses (Li et al, 1998; Harcourt et al, 2004;Tree et al, 2004; Vaughan et al, 2005). DNA vaccines encoding RSV F and G genes provide protection in animals after RSV challenge (Bembridge et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

RSV fusion (F) protein DNA vaccine provides partial protection against viral infection

Dennis

Pillai

et al. 2009

Virus Research

View full text Add to dashboard Cite

The present study was conducted to investigate the feasibility and efficacy of a RSV F DNA vaccine incorporated with a mucosal adjuvant. Two DNA vaccine vectors (DRF-412 and DRF412-P) were developed containing residues 412-524 of the RSV F gene. These antigenic regions were cloned into the phCMV1 DNA vaccine vector. One of the DNA vaccine vectors, DRF-412, contained the ctxA2B region of the cholera toxin gene as a mucosal adjuvant. The in vitro expression of these DNA vectors were confirmed in Cos-7 cells by indirect immunofluorescence and western blot analyses. In vivo expression of the cloned gene was further confirmed in mouse muscle tissue by immunohistological analysis. The active transcription of the RSV F gene in mouse muscle cells was confirmed by RT-PCR. The purified DRF-412 and DRF412-P DNA vectors were used to immunize mice by intramuscular injections. Our results indicated that DRF-412 and DRF412-P vaccine vectors were as effective as live RSV in inducing neutralization antibody, systemic Ab (IgG, IgG1, IgG2a, and IgG2b) responses, and mucosal antibody responses (Ig A). The Th1 (TNF-α, IL-12p70, IFN-γ, IL-2) and Th2 (IL-10, IL-6) cytokine profiles were analyzed after stimulation of spleen cells from mice immunized with purified RF-412 protein. We observed that mice inoculated with vector DRF-412 induced a higher mixed Th1/Th2 cytokine immune response than DRF412-P. Reverse transcriptase and quantitative real-time PCR (qRT-PCR) revealed that mice immunized with the DRF-412 vector contained less viral RNA in lung tissue and the lung immunohistology study confirmed that mice immunized with DRF-412 had better protection than those immunized with the DRF412-P vector. These results indicate that the RSV DRF-412 vaccine vector, which contains the cholera toxin subunit ctxA2B as a mucosal adjuvant may provide a better DNA vaccination strategy against RSV.

show abstract

“…Comparison of intragastric, intranasal and intradermal delivery routes of plasmid DNA encoding RSV F protein encapsulated in PLGA MPs in BALB/c mice has been investigated. Intragastric and intranasal immunization induced very low levels of RSV-specific serum antibodies and did not provide protection against RSV [67]. In contrast, intradermal (i.d.)…”

Section: The Route Of Administrationmentioning

confidence: 99%

“…In contrast, intradermal (i.d.) vaccination elicited strong humoral response, protected animals against RSV infection and promoted pulmonary IgG1 secretion [67]. Similarly, i.d.…”

Section: The Route Of Administrationmentioning

confidence: 99%

Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus

Jorquera

Tripp

2016

Vaccines

View full text Add to dashboard Cite

Synthetic biodegradable microparticle and nanoparticle platform technology provides the opportunity to design particles varying in composition, size, shape and surface properties for application in vaccine development. The use of particle vaccine formulations allows improvement of antigen stability and immunogenicity while allowing targeted delivery and slow release. This technology has been design to develop novel vaccines against the respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infection in infants. In the last decade, several nano- and micro-sized RSV vaccine candidates have been developed and tested in animal models showing promising results. This review provides an overview of recent advances in prophylactic particle vaccines for RSV and the multiple factors that can affect vaccine efficacy.

show abstract

An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung

Cited by 16 publications

References 32 publications

Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus

Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus

RSV fusion (F) protein DNA vaccine provides partial protection against viral infection

Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus

Contact Info

Product

Resources

About